Trial Profile
Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGENESIS INHIBITORS.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2012
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOTOR
- 02 Aug 2011 New trial record